Piper Sandler Rates GeneDx (WGS) buy, $63 Price Target

Piper Sandler maintains its buy rating on GeneDx Holdings Corp. with a price target of $63, a 8.26% downside from the current price.

By TradeTexts Research Desk · Published Jun 23, 2026, 1:02 PM EDT · Updated Jun 26, 2026, 10:02 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Piper Sandler rated GeneDx Holdings Corp. ($WGS) "buy" with a $63 price target on June 23, 2026.

Since the rating, $WGS is up 18.2% after 1 week, up 9.1% after 1 month and up 9.5% to date (from the $58.08 close on Jun 23, 2026).

WGS GeneDx Holdings Corp.

$63.61 -51.92% year to date

Daily close · Oct 16, 2026

Key Points

Piper Sandler reiterated its buy rating on GeneDx Holdings Corp. (WGS) with a price target of $63.
Piper Sandler's $63 price target implies 8.26% downside from GeneDx Holdings Corp.'s ($WGS) current $68.67 share price.
GeneDx shares traded around $55.42 on Tuesday, with a market cap of approximately $1.65 billion.
Key insider transactions include CEO Katherine Stueland selling shares on June 16, 2026.

Get $WGS trade alerts by text

We text you when insiders, Congress or big funds trade $WGS. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated GeneDx Holdings Corp. alert may contain errors. Disclosures

Piper Sandler has reiterated its buy rating on GeneDx Holdings Corp. (NasdaqGS: WGS) with a price target of $63. Analyst David Westenberg maintained the rating on June 23, 2026, as the stock traded around $55.42 on Tuesday.

Analyst rating track record

Piper Sandler vs. the S&P 500

YTD return -14.26% hypothetical

All-time return +28.24% S&P 500 +34.82%

vs. S&P 500 -6.58% behind the index

Hypothetical returns from Piper Sandler's disclosed trades, not real profit or advice. How we model this.

GeneDx Holdings Corp. Stock Down 32.1%

Shares of NasdaqGS:WGS traded near $55.42 on Tuesday. GeneDx Holdings Corp. has a market capitalization of approximately $1.65 billion, a forward P/E ratio of 45.01, and a beta of 1.971. The stock's 52-week range has been between $32.21 and $170.87. It shows a 50-day moving average of $54.79 and a 200-day moving average of $99.42. The company's current ratio is 3.088, with a quick ratio of 2.825 and a debt-to-equity ratio of 66.185.

12-month forecast

$WGS price target

GeneDx Holdings Corp. daily closes and this analyst's $63 target. Not advice.

Recent Earnings

GeneDx Holdings Corp. reported revenue of about $442.7 million, reflecting a growth rate of 17.4%. However, the company is not yet profitable, with a net margin of -17.6% and a return on equity of -30.4%. The next earnings release is expected on July 28, 2026.

Insider Buying and Selling at GeneDx Holdings Corp.

On June 16, 2026, CEO Katherine Stueland sold 10,501 shares at an average price of $60.76. Additionally, CFO Kevin Feeley was involved in multiple transactions on the same day, selling 7,197 shares and buying 7,197 shares, with no price disclosed for the buy transaction.

Analysts Set New Price Targets

On June 23, 2026, Piper Sandler maintained its buy rating on GeneDx Holdings Corp. with a price target of $63. Other firms have also maintained buy ratings recently, including Canaccord Genuity and Wells Fargo, both with a $75 target set on May 5, 2026. The consensus rating is a strong buy, with a mean target price of $77 among nine analysts.

About GeneDx Holdings Corp.

GeneDx Holdings Corp., headquartered in Stamford, Connecticut, is a genomics company that offers genetic testing services, focusing on pediatric and rare diseases. The company specializes in whole exome and genome sequencing and provides data and information services. GeneDx also develops an AI-based platform for next-generation sequencing analysis and clinical reporting. Led by CEO Kevin Feeley, the company employs approximately 1,300 people.

Bottom Line

Piper Sandler's reiterated buy rating on GeneDx Holdings highlights continued confidence in the company's growth potential. Investors keep a close watch on analyst ratings and insider transactions to gauge market sentiment. Remember, 13F filings and analyst reports reflect past activity and may not indicate current positions or future performance.